Open AccessSafe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail
Author(s) -
Boom Louisa,
Stuecher Theresa,
Mader Julia K.
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4811
Subject(s) - medicine , dulaglutide , glycemic , type 2 diabetes , glucagon like peptide 1 receptor , girl , agonist , intensive care medicine , glucagon like peptide 1 , pediatrics , diabetes mellitus , endocrinology , exenatide , insulin , receptor , psychology , developmental psychology
This case report demonstrates that using a non‐approved long‐acting GLP‐1‐RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.